Psychedelics

How does ketamine-assisted psychotherapy help real world patients?

Psychiatrists are trying our ketamine-assisted psychotherapy in their clinical practices. What do patients think of this treatment?

Dr Miller continues her Ketamine Journal with a mini-group of 2 patients and a cofacilitator.

John Krystal, MD, explores the future of ketamine and psychedelics in psychiatry, shedding light on their potential to improve patient care by increasing options treatment options.

Should ketamine be used at all when FDA-approved Spravato is available and insurance will pay for it?

Psychedelics: we first must enlarge our knowledge of how these work, what clinical conditions should be targeted, and how different psychedelics compare to each other.

The FDA instead issued a CRL for MDMA-assisted psychotherapy for PTSD, requesting an additional phase 3 trial to examine safety and efficacy. Other psychedelic compounds are proceeding with trials for psychiatric conditions. Learn more here.

While new treatment options in the PTSD space can be exciting, we cannot lose sight of the treatments that are already readily available.

New phase 1b results of VLS-01, an oral transmucosal film formulation of DMT, show ‘psychologically meaningful’ improvement for patients with treatment-resistant depression.

A phase 3 clinical trial participant shares her thoughts on MDMA-assisted psychotherapy and her trial experience.

Despite the FDA's complete response letter for MDMA-assisted psychotherapy, researchers believe the data behind this PTSD treatment is what matters most.

At least 1 in 2 people experience trauma at some point in their life, and a subset of those individuals will develop PTSD.

After months of preparation, one psychiatrist starts using KAP in her practice.

A mainstream psychiatrist finds herself exploring a treatment that is off the radar for most.

Psychedelics may catalyze rapid improvements in mental health, but they do so firmly rooted in what we already know about the efficacy of psychotherapy.

Learn more about one psychiatrist’s personal experiential learning process with ketamine.

The FDA did not vote to deny approval of MDMA-assisted psychotherapy on June 4, 2024, contrary to all the buzz in the media saying they did. Learn more here.

Here are highlights from the week in Psychiatric Times.

June held negative news for psychedelics and an accepted sNDA for brexpiprazole + sertraline for adults with PTSD.

A look into the experiential learning process involving ketamine.

Here are highlights from the week in Psychiatric Times.

The outcomes of this study are expected to inform the development of the upcoming PATHFINDER-52 phase 2b clinical trial.

Here are highlights from the week in Psychiatric Times.

Following the vote of the US Food and Drug Administration Psychopharmacologic Drugs Advisory Committee, Lykos has released a statement on MDMA-assisted therapy.

The Psychiatric Times Editor-in-Chief discusses the clinical uses and casual prescribing of ketamine for the treatment of psychiatric disorders.

Here are highlights from the week in Psychiatric Times.

Psychiatric Times Editor-in-Chief shares his thoughts on the FDA Psychopharmacologic Drugs Advisory Committee decision for MDMA.

The FDA Psychopharmacologic Drugs Advisory Committee voted against recommending approval for psychedelic MDMA.

The FDA Meeting of the Psychopharmacologic Drugs Advisory Committee evaluating the New Drug Application for MDMA is happening now. How do clinicians feel about this potential treatment for PTSD?